• Toremifene in Prostate Cancer: Evidence Boundaries

  2026-10-14

  Toremifene is a selective estrogen-receptor modulator with a documented research context in hormone-related cancer biology, but the supplied prostate cancer metastasis study does not test Toremifene or establish a connection between estrogen receptor modulation and the TSPAN18–STIM1 calcium-signaling axis.

• Endogenous Melatonin in LPS-Activated Macrophages

  2026-10-13

  A source-grounded overview of a 2024 Experimental Cell Research study examining how LPS-induced macrophage activation affects endogenous melatonin synthesis, and whether that melatonin feeds back on inflammatory polarization, oxidative stress and apoptosis.

• What the ISG20 Atherosclerosis Evidence Shows

  2026-10-12

  A 2025 study links CLEC5A and ISG20 with atherosclerosis using transcriptomic, eQTL and Mendelian-randomization analyses, with additional model-based validation for ISG20. The findings are biologically suggestive but do not establish a clinical treatment target or prove that altered ISG20 activity independently causes human plaque progression.

• Toremifene and the TSPAN18–STIM1 Evidence Gap

  2026-10-12

  The supplied prostate cancer study supports a TSPAN18–STIM1 mechanism in bone-metastasis models, but it does not test Toremifene. Supplier-reported Toremifene activity therefore cannot be used to establish effects on this pathway, therapeutic benefit, or clinical applicability.

• ORAI2 and Early Salivary Gland Fibrosis

  2026-10-11

  The cited study links ORAI2-mediated store-operated calcium entry to early postirradiation salivary-gland fibrosis through a proposed JNK/NFAT1/TGF-β1 pathway. Its multi-model findings are mechanistically coherent but remain preclinical, with important limits concerning pharmacologic specificity, duration, and clinical applicability.

• Boc-D-FMK: Reading Caspase Evidence

  2026-10-10

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor used to test whether caspase activity contributes to apoptosis and inflammation. This article develops an evidence-centered framework linking its interpretation to the 2025 ATF5–CYP2B6 glioblastoma study without overstating mechanistic or translational conclusions.

• Antimycin A4: Evidence, Uses, and Limitations

  2026-10-09

  Antimycin A4 is presented by APExBIO as a mitochondrial respiratory-chain inhibitor and ATP-citrate lyase inhibitor, but the supplied evidence does not independently validate both mechanisms or establish translational applications. This overview separates catalog claims from the supplied peer-reviewed synthesis paper, evaluates conceptual research uses, and defines the main evidence and applicability limits.

• Candida krusei Apoptosis in Bovine Mammary Cells

  2026-10-09

  A 2023 study found that the yeast and hypha phases of Candida krusei induce apoptosis in bovine mammary epithelial cells through different dominant pathways. Its phase-resolved design links yeast-associated injury mainly to mitochondrial signaling, whereas hypha-associated apoptosis is more closely associated with death ligand/receptor signaling and shared TLR–MAPK responses.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-10-08

  The Luminescent ATP Cell Viability Assay Kit I provides a rapid, sensitive ATP-based endpoint for studying ferroptosis and cytotoxic responses. This article explains how luciferase luminescence detection can strengthen mechanistic interpretation without treating viability loss as proof of a specific death pathway.

• How Dual-Action Inhibitors Tune p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that selected kinase inhibitors can do more than block p38α catalytic activity: they can also favor an activation-loop conformation that makes the regulatory phosphothreonine more accessible to WIP1 phosphatase. The structural and biochemical findings introduce a mechanism for coupling kinase inhibition with accelerated dephosphorylation, while remaining an early, primarily reconstituted-system result rather than a clinical or cellular efficacy demonstration.

• Cross-Kingdom Promoters Need Better Readouts

  2026-10-07

  Synthetic promoters that operate across bacteria and yeast could make genetic systems more portable, but portability is only useful when expression can be measured consistently. This thought-leadership article examines the mechanistic rationale, reported validation, translational boundaries, and strategic role of β-galactosidase reporter assays in evaluating cross-kingdom expression systems.

• Bufalin: From Cardiotonic Steroid to Translational Probe

  2026-10-07

  Bufalin is emerging as a mechanistically rich oncology research compound. New pre-proof evidence connects it with CENPA-associated glycolysis, PI3K/AKT signaling, and migration in hepatocellular carcinoma, while broader research positions the cardiotonic steroid as an apoptosis inducer and possible molecular-glue degrader. This article assesses the evidence, translational opportunities, limitations, and strategic questions that should guide future investigation.

• VX-765 and the Blood–Brain Barrier: 5 Questions

  2026-10-06

  A source-grounded overview of what VX-765 reveals about caspase-1 signaling and blood–brain barrier injury, including evidence strength, interpretation, scope, and key limitations.

• Methylprednisolone in Inflammation and Bone Research

  2026-10-05

  Methylprednisolone is a synthetic glucocorticoid receptor agonist studied across inflammatory and skeletal disease models. This overview compares supplier-described anti-inflammatory mechanisms with findings from a 2024 rat study of glucocorticoid-induced osteonecrosis of the femoral head, while emphasizing evidence strength, translational limits, and unresolved questions.

• YM 58483 (BTP2): SOCE, Fibrosis, Translation

  2026-10-05

  YM 58483 (BTP2) offers a pathway-level lens on sustained calcium entry across immune activation and radiation-associated salivary gland fibrosis. This thought-leadership analysis connects SOCE biology with the ORAI2/JNK/NFAT1/TGF-β1 axis while separating reported preclinical findings from translational hypotheses and evidence limitations.

8666 records 1/578 page Next 12345 下5页 Last page